Lee's Pharmaceutical Holdings Limited

950 KYG5438W1116

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.08 ^HKD	-0.92%		-6.90%	-29.41%

Apr. 19	Lee’s Pharmaceutical's 2023 Profit Slumps 67%	MT
Mar. 26	Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024	CI

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

March 26, 2024 at 04:58 am EDT

Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024.

Record date is 31 May 2024. Payment date is 17 June 2024.

Latest news about Lee's Pharmaceutical Holdings Limited

Lee’s Pharmaceutical's 2023 Profit Slumps 67%	Apr. 19	MT
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024	Mar. 26	CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
China Grants Lee's Pharmaceutical Drug Registration for Schizophrenia-Related Agitation Treatment; Shares Rise 3%	Nov. 28	MT
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan	Nov. 14	MT
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 04 October 2023	23-08-30	CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Lee's Pharmaceutical Holdings Unit's Fentanyl Inhalable Reaches Endpoints in Phase 2A Trial	23-08-22	MT
Lee's Pharmaceutical Holdings Limited Announces Phase IIa Clinical Trial of A F fentanyl Aerosol for Inhalation Conducted by Zhaoke Pharmaceutical Limited	23-08-21	CI
Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-08-21	CI
Lee’s Pharmaceutical Gets Registration Certificate for Medical Device to Treat Hypoxic Respiratory Failure	23-06-09	MT
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director	23-05-17	CI
Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 15 June 2023	23-03-30	CI
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Lee’s Pharmaceutical Holdings Warns of Plunge in 2022 Profit	23-03-21	MT
Lee's Pharmaceutical Holdings Limited Provides Group Earnings Guidance for the Year Ended 31 December 2022	23-03-20	CI
Extended Phase 2b Study for Lee's Pharmaceutical's Tafoxiparin Concludes; Shares Slip 3%	23-02-17	MT
Nine Lee's Pharma Products Included in China's National Reimbursement Drug List	23-01-19	MT
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List	23-01-19	CI
Lee's Pharmaceutical's Q3 Profit More Than Doubles	22-11-24	MT
Lee’s Pharmaceutical Q3 Profit Jumps 150%	22-11-17	MT
Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
US FDA Approves Lee's Pharmaceutical's Clinical Trial for Liver Cancer Treatment	22-11-09	MT
Lee's Pharma Unit Completes Enrolment for Phase III Trial for Vulvovaginal Atrophy Treatment; Shares Climb 7%	22-10-27	MT
Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa	22-10-26	CI

Chart Lee's Pharmaceutical Holdings Limited

Duration

Period

Chart Lee's Pharmaceutical Holdings Limited

More charts

Company Profile

Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

1.08 HKD

Average target price

1 HKD

Spread / Average Target

-7.41%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEE'S PHARMACEUTICAL HOLDINGS LIMITED	-29.41%	81.24M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals